© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.